MONTREAL, Jan. 11, 2022 – New research published in Nature Communications suggests that a newly-identified enzyme could reduce sugar and fat in the body and help us live longer healthier lives. The enzyme, Glycerol-3-Phosphate…
Read More
La société et ses partenaires ont obtenu un million de dollars canadiens pour appliquer et améliorer le logiciel de conception virtuelle de médicaments de MFI à l’appui de la recherche…
The company and its partners have secured CAD$1 million to apply and improve MFI’s virtual drug-design software in support of preclinical research targeting antibiotic-resistant bacteria and non-alcoholic fatty liver disease…
adMare BioInnovations, Canada’s global life sciences venture, invites you to join us on Thursday, December 10 at 11:00 am (EST), for the unveiling of the six exciting start-ups selected for our new…
COVID-19 may be keeping us from getting on planes and meeting in person, but it’s not stopping us from continuing to build Canada’s life sciences industry from sea to sea,…
The proceeds from the financing will fund Phase 1 & Phase 2 clinical trials of ZT-01, Zucara’s first-in-class drug candidate designed to prevent hypoglycemia in Type 1 Diabetes (T1D), a frequent, unintended consequence of insulin therapy for people with T1D & other types of insulin-dependent diabetes.
The proceeds from the financing will fund Phase 1 & Phase 2 clinical trials of ZT-01, Zucara’s first-in-class drug candidate designed to prevent hypoglycemia in Type 1 Diabetes (T1D), a frequent, unintended consequence of insulin therapy for people with T1D & other types of insulin-dependent diabetes.
